Rapport Therapeutics (RAPP) Operating Expenses (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Operating Expenses of $44.2 million for Q1 2026, up 63.11% year-over-year from $27.1 million in Q1 2025, and up 14.82% quarter-over-quarter from $38.5 million in Q4 2025.
Rapport Therapeutics (RAPP) Operating Expenses (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Operating Expenses for 4 consecutive years, with $44.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 63.11% year-over-year to $44.2 million; the TTM figure through Mar 2026 stood at $142.2 million (up 52.8% YoY), while the FY2025 annual figure was $125.1 million, up 50.62% from the prior year.
- Operating Expenses grew to $44.2 million in Q1 2026 per RAPP's latest filing, from $38.5 million in the prior quarter.
- Across five years, Operating Expenses topped out at $44.2 million in Q1 2026 and bottomed at $6.6 million in Q2 2023.
- Historically, Operating Expenses has averaged $23.6 million across 4 years, with a median of $22.6 million in 2024.
- Annual changes were most pronounced in 2024 — Operating Expenses jumped 213.73% — and 2025, when it soared 38.57%.
- Rapport Therapeutics' Operating Expenses stood at $14.8 million in 2023, then soared by 58.99% to $23.5 million in 2024, then surged by 63.72% to $38.5 million in 2025, then rose by 14.82% to $44.2 million in 2026.
- Business Quant data shows RAPP's Operating Expenses at $44.2 million in Q1 2026, $38.5 million in Q4 2025, and $30.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 60.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.81 Mn |
| Mar 31, 2026 | 44.22 Mn |
| Dec 31, 2025 | 38.51 Mn |
| Sep 30, 2025 | 29.99 Mn |
| Jun 30, 2025 | 29.50 Mn |
| Mar 31, 2025 | 27.11 Mn |
| Dec 31, 2024 | 23.52 Mn |
| Sep 30, 2024 | 21.64 Mn |
| Jun 30, 2024 | 20.80 Mn |
| Mar 31, 2024 | 17.09 Mn |
| Dec 31, 2023 | 14.79 Mn |
| Sep 30, 2023 | 9.56 Mn |
| Jun 30, 2023 | 6.63 Mn |